Business
KidneyIntelX in Multi-Center Study
KidneyIntelX in Multi-Center Study.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n RNS Number : 8477U\n Renalytix AI PLC\n 03 August 2020\n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n (\"RenalytixAI\", the \"Company\")\n \n \n \n \n \n KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients \n \n \n \n \n \n Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19\n \n \n \n \n \n \n Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients\n \n \n \n \n \n NEW YORK, August 3, 2020\n \n - Mount Sinai Health System and \n \n \n Renalytix AI plc\n \n \n (\n LSE: RENX) (NASDAQ: RNLX), announce the initiation of a multi-center study to conduct in-depth investigations into kidney-related complications and long-term outcomes linked to COVID-19. KidneyIntelX, the artificial intelligence-enabled in vitro diagnostic platform, will be used to assess the risk of kidney disease progression and kidney failure, among other kidney complications, in patients surviving COVID-19 from multiple centers in the United States. As of July 30, 2020, \n \n \n over 300,000 Americans had been hospitalized for COVID-19\n \n \n .1\n \n \n \n \n \n The study, titled\n \n \n \n \"\n M\n ulti-center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID),\" expands on the Pred-MAKER study previously announced April 20, 2020 which focuses on the impact of COVID-19 in the acute hospitalized setting (\n \n \n https://renalytixai.com/kidneyintelx-covid-19/\n \n \n ). Investigative teams expected to participate in the study include the Mount Sinai Health System Icahn School of Medicine at Mount Sinai in New York, Yale New Haven Health/Yale School of Medicine, Michigan Medicine/University of Michigan Medical School, Johns Hopkins Medicine/The Johns Hopkins University Medical School, and Rutgers, The State University of New Jersey/Rutgers New Jersey Medical School. \n \n \n \n \n \n KidneyIntelX will be used to assess risk for new chronic kidney disease (CKD) in the short-term or kidney disease progression over the longer-term in patients who have recovered from COVID-19. \n Diverse data inputs, including validated blood and urine-based biomarkers, inherited genetics and extensive patient data from electronic health record systems, will be incorporated into the KidneyIntelX machine learning-enabled ...